Inducing the transition of M2 macrophages toward M1 phenotype can markedly diminish the quantity of M2 macrophages, augment the release of tumor necrosis factor‐alpha (TNF‐α), interleukin‐6 (IL‐6), and other cytokines, stimulate the antitumor immune response, and promote the eradication of tumor cells.[25, 26] Numerous studies have confirmed that drug delivery systems utilizing this “turning enemies into friends” strategy possess significant efficacy in tumor treatment and offer promising prospects for therapeutic advancement.[27, 28, 29, 30]. Here, IL6 is linked to neoplasm.